Iron chelation by clinically relevant anthracyclines: Alteration in expression of iron-regulated genes and atypical changes in intracellular iron distribution and trafficking

Molecular Pharmacology

Volumn 73, Issue 3, 2008, Pages 833-844

  Xu, X ^a   Sutak, R ^a   Richardson, D R ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CD71 ANTIGEN; CHELATING AGENT; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; FERRITIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IRON; MESSENGER RNA;

ANIMAL CELL; ARTICLE; BINDING SITE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BINDING; DRUG EFFECT; GENE; GENE EXPRESSION; IRON CHELATION; IRON DEFICIENCY; IRON DEPLETION; IRON KINETICS; IRON METABOLISM; IRON TRANSPORT; METAL BINDING; MOUSE; N MYC DOWNSTREAM REGULATED GENE 1; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE C MYB; PRIORITY JOURNAL; TRANSFERRIN RECEPTOR 1 GENE; UPREGULATION;

ANIMALS; ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; CELL CYCLE PROTEINS; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; DAUNORUBICIN; DEFEROXAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; EMBRYO, MAMMALIAN; EPIRUBICIN; FIBROBLASTS; GENE EXPRESSION REGULATION; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; IRON; IRON CHELATING AGENTS; KINETICS; MICE; MICE, KNOCKOUT; MOLECULAR STRUCTURE; MYOCYTES, CARDIAC; PROTEIN BINDING; PROTEIN TRANSPORT; RECEPTORS, TRANSFERRIN; RNA, MESSENGER; SIDEROPHORES;

EID: 40849085410     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.107.041335     Document Type: Article

References (40)

1. Babusiak M, Man P, Sutak R, Petrak J, and Vyoral D (2005) Identification of heme binding protein complexes in murine erythroleukemic cells: study by a novel two-dimensional native separation-liquid chromatography and electrophoresis. Proteomics 5:340-350.
2. Beerepoot LV, Shima DT, Kuroki M, Yeo KT, and Voest EE (1996) Up-regulation of vascular endothelial growth factor production by iron chelators. Cancer Res 56: 3747-3751.
3. Beraldo H, Garnier-Suillerot A, Tosi L, and Lavelle F (1985) Iron(III)-adriamycin and Iron(III)-daunorubicin complexes: physicochemical characteristics, interaction with DNA, and antitumor activity. Biochemistry 24:284-289.
4. Bianchi L, Tacchini L, and Cairo G (1999) HIF-1-mediated activation of transferrin receptor gene transcription by iron chelation. Nucleic Acids Res 27:4223-4227.
5. Bruick RK (2000) Expression of the gene encoding the proapoptotic Nip3 protein is induced by hypoxia. Proc Natl Acad Sci U S A 97:9082-9087.
6. Chen S, Garami M, and Gardner DG (1999) Doxorubicin selectively inhibits brain versus atrial natriuretic peptide gene expression in cultured neonatal rat myocytes. Hypertension 34:1223-1231.
7. Corna G, Santambrogio P, Minotti G, and Cairo G (2004) Doxorubicin paradoxically protects cardiomyocytes against iron-mediated toxicity: role of reactive oxygen species and ferritin. J Biol Chem 279:13738-13745.
8. Gianni L and Myers C (1992) The role of free radical formation in the cardiotoxicity of anthracyclines, in Cancer Treatment and the Heart (Franco MM, Green MD, and Speyer JL eds) pp 9-46, Johns Hopkins University Press, Baltimore, MD.
9. Gu YZ, Moran SM, Hogenesch JB, Wartman L, and Bradfield CA (1998) Molecular characterization and chromosomal localization of a third alpha-class hypoxia inducible factor subunit, HIF3alpha. Gene Expr 7:205-213.
10. Helton R, Cui J, Scheel JR, Ellison JA, Ames C, Gibson C, Blouw B, Ouyang L, Dragatsis I, Zeitlin S, et al. (2005) Brain-specific knock-out of hypoxia-inducible factor-1alpha reduces rather than increases hypoxic-ischemic damage. J Neurosci 25:4099-4107.
11. Hentze MW and Kuhn LC (1996) Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide, and oxidative stress. Proc Natl Acad Sci U S A 93:8175-8182.
12. Hershko C, Link G, Tzahor M, Kaltwasser JP, Athias P, Grynberg A, and Pinson A (1993) Anthracycline toxicity is potentiated by iron and inhibited by desferoxamine: studies in rat heart cells in culture. J Lab Clin Med 122:245-251.
13. Hu CJ, Wang LY, Chodosh LA, Keith B, and Simon MC (2003) Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol Cell Biol 23:9361-9374.
14. Hurwitz SJ, Terashima M, Mizunuma N, and Slapak CA (1997) Vesicular anthracycline accumulation in doxorubicin-selected U-937 cells: participation of lysosomes. Blood 89:3745-3754.
15. Ito H, Miller SC, Billingham ME, Akimoto H, Torti SV, Wade R, Gahlmann R, Lyons G, Kedes L, and Torti FM (1990) Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and in vitro. Proc Natl Acad Sci U S A 87:4275-4279.
16. Jung K and Reszka R (2001) Mitochondria as subcellular targets for clinically useful anthracyclines. Adv Drug Deliv Rev 49:87-105.
17. Kaiserová H, Simunek T, Sterba M, den Hartog GJ, Schroterova L, Popelova O, Gersl V, Kvasnickova E, and Bast A (2007) New iron chelators in anthracycline-induced cardiotoxicity. Cardiovasc Toxicol 7:145-150.
18. Kalinowski D and Richardson DR (2005) Evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol Rev 57:1-37.
19. Kotamraju S, Chitambar CR, Kalivendi SV, Joseph J, and Kalyanaraman B (2002) Transferrin receptor-dependent iron uptake is responsible for doxorubicinmediated apoptosis in endothelial cells: role of oxidant-induced iron signaling in apoptosis. J Biol Chem 277:17179-17187.
20. Kovacevic Z and Richardson DR (2006) The metastasis suppressor, Ndrg-1: a new ally in the fight against cancer. Carcinogenesis 27:2355-2366.
21. Kwok JC and Richardson DR (2002) Unexpected anthracycline-mediated alterations in iron-regulatory protein-RNA-binding activity: the iron and copper complexes of anthracyclines decrease RNA-binding activity. Mol Pharmacol 62:888-900.
22. Kwok JC and Richardson DR (2003) Anthracyclines induce accumulation of iron in ferritin in myocardial and neoplastic cells: inhibition of the ferritin iron mobilization pathway. Mol Pharmacol 63:849-861.
23. Kwok JC and Richardson DR (2004) Examination of the mechanism(s) involved in doxorubicin-mediated iron accumulation in ferritin: studies using metabolic inhibitors, protein synthesis inhibitors, and lysosomotropic agents. Mol Pharmacol 65:181-195.
24. Le NT and Richardson DR (2004) Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation. Blood 104:2967-2975.
25. Link G, Tirosh R, Pinson A, and Hershko C (1996) Role of iron in the potentiation of anthracycline cardiotoxicity: identification of heart cell mitochondria as a major site of iron-anthracycline-iron complex. J Lab Clin Med 127:272-278.
26. Lok CN and Ponka P (1999) Identification of a hypoxia response element in the transferrin receptor gene. J Biol Chem 274:24147-24152.
27. May PM, Williams GK, and Williams DR (1980) Solution chemistry studies of adriamycin-iron complexes present in vivo. Eur J Cancer 16:1275-1276.
28. Minotti G, Menna P, Salvatorelli E, Cairo G, and Gianni L (2004a) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56:185-229.
29. Minotti G, Recalcati S, Menna P, Salvatorelli E, Corna G, and Cairo G (2004b) Doxorubicin cardiotoxicity and the control of iron metabolism: quinone-dependent and independent mechanisms. Methods Enzymol 378:340-361.
30. Minotti G, Ronchi R, Salvatorelli E, Menna P, and Cairo G (2001) Doxorubicin irreversibly inactivates iron regulatory proteins 1 and 2 in cardiomyocytes: evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy. Cancer Res 61:8422-8428.
31. Miura T, Muraoka S, and Ogiso T (1991) Lipid peroxidation of rat erythrocyte membrane induced by adriamycin-Fe3+. Pharmacol Toxicol 69:296-300.
32. Pantopoulos K and Hentze MW (1995) Rapid responses to oxidative stress mediated by iron regulatory protein. EMBO J 14:2917-2924.
33. Ponka P, Borova J, Neuwirt J, Fuchs O, and Necas E (1979) A study of intracellular iron metabolism using pyridoxal isonicotinoyl hydrazone and other synthetic chelating agents. Biochim Biophys Acta 586:278-297.
34. Richardson DR and Milnes K (1997) The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents II: the mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone. Blood 89:3025-3038.
35. Richardson DR, Tran EH, and Ponka P (1995) The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood 86:4295-4306.
36. Ryan HE PM, McNulty W, Elson D, Gassmann M, Arbeit JM, and Johnson RS (2000) Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth. Cancer Res 60:4010-4015.
37. Tarr M and van Helden PD (1990) Inhibition of transcription by adriamycin is a consequence of the loss of negative superhelicity in DNA mediated by topoisomerase II. Mol Cell Biochem 93:141-146.
38. Watts RN and Richardson DR (2002) The mechanism of nitrogen monoxide (NO)-mediated iron mobilization from cells. NO intercepts iron before incorporation into ferritin and indirectly mobilizes iron from ferritin in a glutathione-dependent manner. Eur J Biochem 269:3383-3392.
39. Wood SM, Wiesener MS, Yeates KM, Okada N, Pugh CW, Maxwell PH, and Ratcliffe PJ (1998) Selection and analysis of a mutant cell line defective in the hypoxiainducible factor-1α-subunit (HIF-1α). Characterization of hif-1α-dependent and -independent hypoxia-inducible gene expression. J Biol Chem 273:8360-8368.
40. Xu X, Persson HL, and Richardson DR (2005) Molecular pharmacology of the interaction of anthracyclines with iron. Mol Pharmacol 68:261-271.